ELSEVIER

Author Index
Volumes 39 and 40

A
Agrawal DK, 39:51, 39:163, 40:109
Alexander B, 39:185, 40:227
Andrews JM, 39:9
Aslam M, 39:185
Atkins B, 39:125
Avaro S, 40:95

B
Bai C, 40:39
Balakrishnan S, 40:87
Balogh GE, 39:91
Bäder S, 40:63
Beart PM, 39:155
Beckers J-F, 39:109
Bedioui F, 40:95
Belloli C, 40:221
Benatti L, 40:27
Benjamin IS, 39:185, 40:227
Beretta C, 40:221
Biwersi J, 40:39
Bomzon A, 39:75
Brady MT, 39:169
Bretheim PT, 39:9
Brien JF, 39:125, 39:235

C
Calderone V, 39:129, 40:57, 40:207
Callaway JK, 39:155
Campbell KE, 39:229
Carcano R, 40:221
Chan E, 40:191
Chapman RW, 39:97
Chay SH, 39:29
Chen X, 39:63
Chi L, 39:193
Chong BTY, 39:163, 40:109
Cilia J, 40:21
Cimiotti-Kolb G, 39:117
Coiffard C, 39:143
Cox EH, 39:19
Cudworth GC II, 40:1

D
Danhof M, 39:19
Dash AK, 40:1
De Jong PE, 39:45
De Jongste J, 40:13
De Roeck-Holtzhauer Y, 39:143
De Vries J, 40:13
De Zeeuw D, 39:45
Delaunois A, 39:109
Demiryürek AT, 39:179
Depierre JW, 40:137
Deveney AM, 40:71
Dhawan BM, 40:173
Doklea E, 40:63
Dumont AS, 40:181
Dunlop J, 40:47

E
Egan RW, 39:97
Evans BAJ, 39:229

F
Fey TA, 39:9
Fichtl B, 40:63
Forsberg T, 40:71
Fujibayashi K, 40:33
Futamura Y, 39:147

G
Gallagher KP, 39:193
Gamache DA, 39:169
Genton M, 39:103
Georgieff M, 40:63
Germann P-G, 40:101
Giancarlo GM, 40:235
Goodwin PA, 39:229

Journal of Pharmacological and Toxicological Methods 40, 245–247 (1998)

© 1999 Elsevier Science Inc. All rights reserved.

655 Avenue of the Americas, New York, NY 10010

1056-8719/98/$–see front matter
PII S1056-8719(98)00030-1

JPM Vol. 40, No. 4
November 1998:245–247

Gossett KA, 39:137
Graff G, 39:169
Granda BW, 40:235
Greenblatt DJ, 40:235
Gustin P, 39:109

H
Hagan JJ, 40:21
Hatori N, 39:81
Häfner D, 40:101
Hedaya MA, 39:1
Hei Y-J, 40:123
Herman JL, 39:29
Herrmann C, 39:117
Holland WP, 40:13
Hope W, 40:151, 40:165
Hsieh GC, 39:9
Hunter WJ III, 39:51
Hurlbert RJ, 40:181
Hussain A, 39:235

I
Irimura K, 39:221

J
Jackson DM, 40:71
Jarrott B, 39:155
Jin Z-Q, 39:63
Jung J-S, 39:71

K
Kaga N, 39:147
Kajikawa S, 39:147
Kakinuma C, 39:147
Karlsson H, 40:137
Kim D-H, 39:71
Kim Y-H, 39:71
Kimura KA, 39:125
Kjellström Å, 40:71
Knoop FC, 39:51
Koiter J, 39:45
Krause RA, 39:9
Kreutner W, 39:97
Kritzler JS, 39:241
Kubota K, 40:33

L
Lang K, 39:117
Langemeijer MWE, 39:19
Lelong IH, 39:203, 39:211
Lichtman AH, 40:81
Liebl B, 40:63
Lin P, 40:145
Luly JR, 39:9
Luppi A, 40:27

M
Maccario J, 39:103
Marks GS, 39:235
Martelli F, 40:27
Martinotti E, 40:57, 40:207
Marx T, 40:63
Matthay MA, 40:39
Mattsson C, 39:81
McNeill JR, 40:87
Mentré F, 39:103
Mertz TE, 39:193
Metz AL, 39:193
Mollison KW, 9
Montagnoli G, 40:27
Monteith GR, 40:183
Morgan SJ, 39:9
Murphy DJ, 39:137
Mückter H, 40:63

N
Nakatsu K, 39:235
Nässberger L, 40:137
Navis G, 39:45
Nemmar A, 39:109
Nordlander R, 39:81
Nyska A, 39:241

O
Oka T, 39:221

P
Pai J, 39:51
Pan W-J, 39:1
Papp JGY, 39:91
Pataricza J, 39:91
Patron-Bizet F, 39:103
Penke B, 39:91
Penning DH, 39:125
Piper DC, 40:21
Podesta A, 40:27
Poucher SM, 40:211
Price JA, 40:117
Pu Y, 40:145

R
Raibstein I, 39:241
Rebel G, 39:203, 39:211
Renninger JP, 39:137
Reynolds JD, 39:125
Rivalland P, 39:143
Rogers KL, 39:193
Romero FA, 39:163, 40:109
Roufogalis BD, 40:183
Rowland M, 39:35
Rydén L, 39:81

S
Saganek LJ, 39:193
Sahin S, 39:35
Saito K, 40:33
Salem A, 40:151, 40:165
Saraswat B, 40:173
Schechter LE, 40:47
Schilling A, 39:97
Selig W, 39:97
Seymour AA, 40:201
Sherwood JE, 39:97
Sherwood R, 40:227
Shibutani Y, 39:147
Sjöquist P-O, 39:81
Smith DL, 40:47
Song D-K, 39:71
Spellman JM, 39:169
Suh H-W, 39:71
Sulon J, 39:109

T
Takahashi T, 40:33
Tatchum-Talom R, 40:87
Tesfamariam B, 40:201
Thomas-Haimez C, 39:103
Tiddens HAWM, 40:13
Townley RG, 39:163, 40:109

U
Uprichard ACG, 39:193
Upton N, 40:21
Urida Y, 39:81

V
Van der Graaf PH, 40:241
Van Gilst WH, 39:45
Verhulst C, 143
Verkman AS, 40:39
Verma S, 40:181
Vilaine JP, 40:95
Villani C, 40:27
Villeneuve N, 40:95
Visen PKS, 40:173
Voituriez K, 40:95
von Moltke LL, 40:235
Vukomanovic DV, 39:235

W
Waldron T, 40:201
Wang Q-D, 39:81
Wanigasekara Y, 40:183
Wann KT, 39:229
Wormser U, 39:241

X
Xie Y, 40:137

Y
Yanagisawa M, 40:33
Yang W, 40:227
Yanni JM, 39:169
Yildiz G, 39:179
Young S, 39:97
Yuasa C, 39:221

Z
Zeballos GA, 39:125
Zhang Y, 40:47
Zhou Q, 40:191
Zoutman DE, 39:235
Zwing M, 40:63

ELSEVIER

Subject Index
Volumes 39 and 40

A

Accelerometer
  miniature, 40:201
ACE, 39:45
ACE-assay, 39:45
Activity, 40:71
Acute pancreatitis, 39:221
Adenosine, 40:211
α-Adrenergic drugs, 40:221
β-Adrenergic drugs, 40:221
β_2-Adrenergic receptors, 40:201
β-Adrenoceptors, 40:109
Adsorptive stripping voltammetry, 39:235
African green monkey, 40:201
Agonist affinity, 40:241
β-Agonist selectivity, 40:221
Agonists
  partial, 40:207
β-Agonists, 40:109
Airway segments, 40:13
Airways, 39:163, 40:109
Albuterol, 40:109
Alcohol, 39:221
Alfentanil, 39:19
d-Amphetamine, 40:71
Analgesia, 39:19, 40:33
  epidural, 40:181
Analysis, 39:235
Anesthesia, 40:63
Angiotensin-converting enzyme (ACE), 39:45
Animal models, 39:1, 39:193, 40:39
Antagonists, 39:129
Anti-inflammatories, 40:165
Anticoagulants, 40:191
Antinociception, 40:81
Antioxidants, 39:155
Antiproliferation, 39:117
ARDS-model, 40:101
Arginine vasopressin, 40:87
Aspirin, 39:81
Asthma, 39:163, 40:109
Atherosclerosis, 39:51
ATPase, 40:183
Automated protocols, 40:63
Autoradiography
  quantitative whole-body, 39:29

B

Behavior
  temperature effects, 40:71
Bicarbonate
  39:203
Bile duct manipulation, 39:75
Biodegradable, 40:1
Blood coagulation, 40:191
Blood pressure, 40:71, 40:87
Blood specimen collection, 40:191
Bovine, 40:27
Bronchial responsiveness, 40:13
Bronchial smooth muscle, 40:13
Bronchoconstriction, 39:163, 40:109
Buffer, 39:203, 39:211

C

C fibers, 39:109
Caecum test, 20:221
Calcium, 40:183
Calcium efflux, 40:183
Calcium pump, 40:183
Cannabinoids, 40:81
Capsaicin, 40:33
Cardiovascular system, 39:75
Cell adhesion molecules, 39:51
Cerebral cortex, 39:125
Chlamydia pneumoniae, 39:51
Chromatography, 40:117
Clenbuterol, 40:27
Co-enzyme Q_{10}, 40:191
Cocaine, 39:1
Common marmoset, 40:21
Competitive antagonism, 39:129
Computational method, 40:117
Computers, 40:117
Concentration-effect relationship, 39:103

Journal of Pharmacological and Toxicological Methods 40, 249–252 (1998)

© 1999 Elsevier Science Inc. All rights reserved.

655 Avenue of the Americas, New York, NY 10010

1056-8719/98/$–see front matter
PII S1056-8719(98)00031-3

JPM Vol. 40, No. 4
November 1998:249–252

Corticosterone, 39:71
Culture media, 39:203, 39:211
Curative effects, 40:173
Cyclic AMP, 40:47
Cyclosporine, 39:9
Cystic fibrosis, 40:39
Cytotoxicity, 39:143

D
Delayed effect, 39:221
Delivery
  preterm, 39:147
Desensitization, 40:109
Developmental toxicology, 39:29
Dimethylthiazole-diphenyl tetrazolium bromide (MTT)
    metabolism, 39:143
1,1-Diphenyl-2-picryl-hydrazyl (DPPH), 39:63
Dissociation constant, 39:129, 40:57, 40:207
DNA synthesis, 39:117
Dogs, 39:97
Dosage forms, 40:1
(±)8-OH-DPAT, 40:71
Drug delivery systems, 40:1
Drug interactions, 40:191, 40:235
Dual perfusion, 39:35

E
Ear-heart transplantation, 39:9
Edema
  interstitial, 40:101
EDRF, 40:95
Electrochemical detection, 40:95
Electron spin resonance (ESR), 39:63
ELISA, 39:117, 40:27
E_{max} model, 39:103
Endothelium, 39:51, 40:95
Endotoxin-induced uveitis, 39:169
Epibatidine, 40:81
Epidermis, 40:145
Epidural analgesia, 40:181
Exocrine hyperstimulation, 39:221

F
Fibrinogen, 39:51
Fibroblast culture, 39:143
Fibroblasts, 39:229
Fowl caecum test, 20:221
Free radicals, 39:63, 39:155
Furchgott's method, 40:57

G
Gas exchange, 40:101
Global two-stage method, 39:103
Glycerol, 40:39
Granulocytes
  margination, 40:101

H
Heart rate, 40:71
Heat output, 40:137
α-Helical corticotropin-releasing factor (CRF) 9-41,
    39:71
Hematocrit, 39:185
Heparin, 39:81
  low molecular weight, 39:193
Hepatic oxygen uptake, 39:185
Hepatocytes, 40:173
Hepatotoxins, 40:173
HEPES, 39:203
High-molecular weight serum cytotoxic factor, 39:241
Hill slope, 40:241
Histamine response, 39:163
Histopathological changes, 40:101
5-HT_{1A} receptor, 40:47
Human 5-HT_{1A} receptor, 40:47
Hyaline membrane formation, 40:101
Hyperaemia, 40:211
Hypoxia, 39:185

I
IHC, 39:51
Implantable pumps, 40:1
Implants, 40:1
In vitro exposure, 40:63
Inflammation, 39:169
Inhalation anesthetics, 40:63
Insulin, 40:123
Insulin signal transduction, 40:123
Interferon γ, 39:51
Interleukin-1β, 39:51, 40:109
Interstitial edema, 40:101
Intracerebroventricular injection, 39:71
Iron-dependent lipid peroxidase, 39:15
Irreversible receptor inactivation method, 40:57, 40:
    241
Ischemia/reperfusion, 39:81
Isobaric contraction, 40:13
Isolated heart, 39:63
Isolated rat liver perfusion, 39:185, 40:227
Isolation, 40:145

L
Lactate dehydrogenase, 40:63
Leflunomide, 39:9
Lipid peroxidation, 39:63
Lipoteichoic acid, 39:147
Liver function tests, 39:35, 39:185, 40:227
LLC-PK_1 cells, 40:137
Low molecular weight heparin, 39:193
Lung function, 39:137
Lung perusates, 39:109

M
Malondialdehyde, 39:155
MAP kinase-cascade, 40:123
Margination of granulocytes, 40:101
Marmosets, 40:21
Membrane fluidity, 39:63
Methacholine, 40:109
Mice, 39:71, 39:147, 40:39
Microcalorimeter, 40:137
Microchip, 40:21
Microdialysis, 39:125
Microphysiometer, 40:47
Microplates, 40:137
Miniature accelerometer, 40:201
Mitogen activated protein (MAP) kinase-cascade, 40:123
Model, 39:169
Morphine dependence
  development, 40:151, 40:159
Morphine emulsions, 40:159
3-Morpholinosydnonimine, 39:91
MTT, 39:143
Mucociliary transport, 40:165
Mucolytics, 40:165
Myeloperoxidase, 39:169

N
Neonatal rats, 40:33
Neuroblastoma cells
  SH-SY5Y, 39:241
Neutral red (NR) assay, 39:117, 39:143
Neutrophil influx, 39:169
Nicorandil, 39:91
Nicotine, 40:81
Nitrate and nitrite anion, 39:125
Nitric oxide, 39:91, 39:125, 39:235, 40:95
Nitric oxide sensor, 40:95
Nitroglycerine, 39:91
S-Nitrosothiol, 39:235
NK_1/NK_2-receptor antagonists, 39:97
Nociceptive response quantification, 40:33
Nonbiodegradable, 40:1
Nonlinear mixed effects model, 39:103
Nonlinear regression, 39:103
NONMEM, 39:19

O
Occlusive vascular disease, 39:51
Ocular, 39:169
Operational model of agonism, 40:241
Opioids, 40:81
Ouabain, 40:137
Ovine fetus, 39:125
Oxygen uptake
  hepatic, 39:185

P
Pain
  postoperative, 40:181
Pancreatitis
  acute, 39:221
Partial agonists, 40:207
Patch-clamp, 39:229
PCR, 39:51
Perfused rat liver, 39:35, 39:185, 40:227
pH, 39:203
Pharmacodynamic modeling, 39:1, 39:19, 40:191
Pharmacokinetic modeling, 39:1, 39:19, 40:191
Pharmacokinetics/pharmacodynamics, 39:1, 39:19, 40:191
Picroliv, 40:173
Pigs, 39:81
Placental transfer, 39:29
Plasma K^+, 40:201
Plethysmograph, 40:13
  whole-body, 39:163
Pleural pressure, 39:137
Polarographic detector, 39:91
Postoperative pain, 40:181
Potassium channel, 39:229
Preclinical pharmacology, 39:103
Pressor responsiveness, 39:75
Preterm delivery, 39:147
Protease inhibitors, 40:235
Pulmonary emphysema, 40:165
Pulmonary function, 39:163
Pyruvic acid consumption, 39:143

Q
Quantification of nociceptive response, 40:33
Quantitative whole-body autoradiography, 39:29

JPM Vol. 40, No. 4
November 1998:249–252

R
Rabbits, 39:29, 39:109, 39:193
Radioimmunoassay, 39:109
Radiotelemetry, 40:71, 40:87
Rats, 39:35, 39:137, 39:185, 39:221, 39:241, 40:33, 40:71, 40:151, 40:227, 159
Receptor-related transduction, 40:57
Receptor theory, 40:241
Recovery, 40:27
Rectal temperature, 40:21
Respiration, 39:137
Restenosis, 39:51
Ritonavir, 40:235

S
Seasonal variation, 40:151
Serum cytotoxic factor
  high-molecular weight, 39:241
SH-SY5Y neuroblastoma cells, 39:241
Sham-operation, 39:75
Shunts, 39:193
Single channel, 39:229
Sirolimus, 39:9
SKF-99101H, 40:21
Smooth muscle
  bronchial, 40:13
  vascular, 39:51
Sodium laurylsulfate cytotoxicity, 39:143
Sodium nitroprusside, 39:91
Sodium-potassium pump, 40:137
Spinal surgery, 40:181
Spontaneously hypertensive rats, 40:87
Stress model, 39:71
Subcutaneous temperature, 40:21
Substance P, 39:109
Superovulation, 39:9
Surgery, 39:35

T
Tachykinins, 39:97
Tacrolimus, 39:9
Tail-flick, 40:81
Taurine, 39:211
TEM, 39:51
Temperature
  behavior effects, 40:71
  rectal, 40:21
  subcutaneous, 40:21
Thiobarbituric acid reacting substances, 39:155
Thiol derivatives, 40:165
Thrombin inhibitor, 39:81
Thrombolysis, 39:81
Thrombosis, 39:193
Time course, 40:101
Tissue ACE, 39:45
Tissue culture, 39:117
Tissue residues, 40:27
Tooth pulp evoked potentials, 39:19
Toxic effects, 39:117
Toxicology
  developmental, 39:29
Transmission electron microscopy (TEM), 39:51
Transport studies, 39:211
Tremor, 40:201
Trimethylamine oxide, 40:39
Triphenyl phosphite, 39:241

U
Urea, 39:35
Uveitis
  endotoxin-induced, 39:169

V
Vascular disease
  occlusive, 39:51
Vascular smooth muscle, 39:51
Vascular steal, 40:211
Vasodilator and liver viability, 40:227
Veal calves, 40:27
Vena cava, 39:193
Venous blood flow, 39:193

W
Warfarin, 40:191
Water permeation barrier, 40:145
Whole-body plethysmograph, 39:163